The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Targeting p53 as a general tumor antigen.
Open accessAbstract
A major barrier to the design of immunotherapeutics and vaccines for cancer is the idiosyncratic nature of many tumor antigens and the possibility that T cells may be tolerant of broadly distributed antigens. We have devised an experimental strategy that exploits species differences in protein sequences to circumvent tolerance of high-affinity T cells. HLA transgenic mice were used to obtain cytotoxic T lymphocytes specific for peptides from the human p53 tumor-suppressor molecule presented in association with HLA-A2.1. Although such p53-specific cytotoxic T cells did not recognize nontransformed human cells, they were able to lyse a wide variety of human tumor cells lines, thus confirming the existence of broadly distributed determinants that may serve as targets for immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
Sallusto, F., & Lanzavecchia, A. (1994) · The Journal of Experimental Medicine · doi:10.1084/jem.179.4.1109 · Cited by 5,129
Tolerance, Danger, and the Extended Family
Matzinger, P. (1994) · Annual Review of Immunology · doi:10.1146/annurev.iy.12.040194.005015 · Cited by 4,820
The p53 tumour suppressor gene
Levine, A. J., Momand, J., & Finlay, C. A. (1991) · Nature · doi:10.1038/351453a0 · Cited by 3,788
Self-citationMutations in the p53 gene occur in diverse human tumour types
Nigro, J. M., Baker, S. J., Preisinger, A. C., Jessup, J. M., Hosteller, R., Cleary, K., Signer, S. H., Davidson, N., Baylin, S., Devilee, P., et al. (1989) · Nature · doi:10.1038/342705a0 · Cited by 2,733
Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules
Falk, K., Rötzschke, O., Stevanovié, S., Jung, G., & Rammensee, H.-G. (1991) · Nature · doi:10.1038/351290a0 · Cited by 2,411
T cell tolerance by clonal elimination in the thymus
Kappler, J. W., Roehm, N., & Marrack, P. (1987) · Cell · doi:10.1016/0092-8674(87)90568-x · Cited by 2,211
Tumor Antigens Recognized by T Lymphocytes
Boon, T., Cerottini, J.-C., Van den Eynde, B., van der Bruggen, P., & Van Pel, A. (1994) · Annual Review of Immunology · doi:10.1146/annurev.iy.12.040194.002005 · Cited by 1,221
Characterization of Peptides Bound to the Class I MHC Molecule HLA-A2.1 by Mass Spectrometry
Hunt, D. F., Henderson, R. A., Shabanowitz, J., Sakaguchi, K., Michel, H., Sevilir, N., Cox, A. L., Appella, E., & Engelhard, V. H. (1992) · Science · doi:10.1126/science.1546328 · Cited by 1,198
Baker, S. J., Preisinger, A. C., Jessup, J. M., Paraskeva, C., Markowitz, S. D., Willson, J. K. V., Hamilton, S. R., & Vogelstein, B. (1990) · PubMed · Cited by 1,063
Kappler, J. W., Staerz, U., White, J., & Marrack, P. C. (1988) · Nature · doi:10.1038/332035a0 · Cited by 1,004
p53 mutations in colorectal cancer.
Rodrigues, N. R., Rowan, A., Smith, M. E., Kerr, I. B., Bodmer, W. F., Gannon, J. V., & Lane, D. P. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.19.7555 · Cited by 1,003
Gain of function mutations in p53
Dittmer, D., Pati, S., Zambetti, G., Chu, S., Teresky, A. K., Moore, M., Finlay, C., & Levine, A. J. (1993) · Nature Genetics · doi:10.1038/ng0593-42 · Cited by 894
Self-citationT-cell receptor Vβ use predicts reactivity and tolerance to Mlsa- encoded antigens
MacDonald, H. R., Schneider, R., Lees, R. K., Howe, R. C., Acha-Orbea, H., Festenstein, H., Zinkernagel, R. M., & Hengartner, H. (1988) · Nature · doi:10.1038/332040a0 · Cited by 888
Gaidano, G., Ballerini, P., Gong, J. Z., Inghirami, G., Neri, A., Newcomb, E. W., Magrath, I. T., Knowles, D. M., & Dalla-Favera, R. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.12.5413 · Cited by 885
Sette, A., Vitiello, A., Reherman, B., Fowler, P., Nayersina, R., Kast, W. M., Melief, C. J. M., Oseroff, C., Yuan, L., Ruppert, J., et al. (1994) · The Journal of Immunology · doi:10.4049/jimmunol.153.12.5586 · Cited by 830
Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells
Rötzschke, O., Falk, K., Deres, K., Schild, H., Norda, M., Metzger, J., Jung, G., & Rammensee, H.-G. (1990) · Nature · doi:10.1038/348252a0 · Cited by 769
Isolation of an endogenously processed immunodominant viral peptide from the class I H–2Kb molecule
Bleek, G. M. V., & Nathenson, S. G. (1990) · Nature · doi:10.1038/348213a0 · Cited by 679
Evidence for a differential avidity model of T cell selection in the thymus
Ashton-Rickardt, P. G., Bandeira, A., Delaney, J. R., Van Kaer, L., Pircher, H.-P., Zinkernagel, R. M., & Tonegawa, S. (1994) · Cell · doi:10.1016/0092-8674(94)90505-3 · Cited by 668
Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules
Ruppert, J., Sidney, J., Celis, E., Kubo, R. T., Grey, H. M., & Sette, A. (1993) · Cell · doi:10.1016/0092-8674(93)90472-3 · Cited by 628
Identification of human cancers deficient in antigen processing.
Restifo, N. P., Esquivel, F., Kawakami, Y., Yewdell, J. W., Mulé, J. J., Rosenberg, S. A., & Bennink, J. R. (1993) · The Journal of experimental medicine · doi:10.1084/jem.177.2.265 · Cited by 624
Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines.
Bártek, J., Iggo, R. D., Gannon, J., & Lane, D. P. (1990) · PubMed · Cited by 603
Hinds, P. W., Finlay, C. A., Quartin, R. S., Baker, S. J., Fearon, E. R., Vogelstein, B., & Levine, A. J. (1990) · PubMed · Cited by 476
Self-citationRearrangement of the p53 gene in human osteogenic sarcomas.
Masuda, H., Miller, C., Koeffler, H. P., Battifora, H., & Cline, M. J. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.21.7716 · Cited by 474
p53 cellular tumor antigen: analysis of mRNA levels in normal adult tissues, embryos, and tumors.
Rogel, A., Popliker, M., Webb, C. G., & Oren, M. (1985) · Molecular and Cellular Biology · doi:10.1128/mcb.5.10.2851 · Cited by 378
Kast, W. M., Brandt, R. M. P., Sidney, J., Drijfhout, J. W., Kubo, R. T., Grey, H. M., Melief, C. J. M., & Sette, A. (1994) · The Journal of Immunology · doi:10.4049/jimmunol.152.8.3904 · Cited by 345
Vitiello, A., Marchesini, D., Furze, J., Sherman, L. A., & Chesnut, R. W. (1991) · The Journal of experimental medicine · doi:10.1084/jem.173.4.1007 · Cited by 311
Self-citationDefinition of specific peptide motifs for four major HLA-A alleles.
Kubo, R. T., Sette, A., Grey, H. M., Appella, E., Sakaguchi, K., Zhu, N. Z., Arnott, D., Sherman, N., Shabanowitz, J., Michel, H., et al. (1994) · The Journal of Immunology · doi:10.4049/jimmunol.152.8.3913 · Cited by 280
Falk, K., Rötzschke, O., Deres, K., Metzger, J., Jung, G., & Rammensee, H. G. (1991) · The Journal of experimental medicine · doi:10.1084/jem.174.2.425 · Cited by 266
Houbiers, J. G. A., Nijman, H. W., Van Der Burg, S. H., Drijfhout, J. W., Kenemans, P., Van De Velde, C. J. H., Brand, A., Momburg, F., Kast, W. M., & Melief, C. J. M. (1993) · European Journal of Immunology · doi:10.1002/eji.1830230905 · Cited by 258
Lower receptor avidity required for thymic clonal deletion than for effector T-cell function
Pircher, H., Rohrer, U. H., Moskophidis, D., Zinkernagel, R. M., & Hengartner, H. (1991) · Nature · doi:10.1038/351482a0 · Cited by 254
Monoclonal antibody to a human histocompatibility alloantigen, HLA-A2
PARHAM, P., & BODMER, W. F. (1978) · Nature · doi:10.1038/276397a0 · Cited by 236
Sequence motifs important for peptide binding to the human MHC class I molecule, HLA-A2
Parker, K. C., Bednarek, M. A., Hull, L. K., Utz, U., Cunningham, B., Zweerink, H. J., Biddison, W. E., & Coligan, J. E. (1992) · The Journal of Immunology · doi:10.4049/jimmunol.149.11.3580 · Cited by 235
Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma.
Noguchi, Y., Richards, E. C., Chen, Y. T., & Old, L. J. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.6.2219 · Cited by 212
Molecular cloning and in vitro expression of a cDNA clone for human cellular tumor antigen p53.
Harlow, E., Williamson, N. M., Ralston, R., Helfman, D. M., & Adams, T. E. (1985) · Molecular and Cellular Biology · doi:10.1128/mcb.5.7.1601 · Cited by 174
A mouse mutant p53 product recognized by CD4+ and CD8+ T cells.
Noguchi, Y., Chen, Y. T., & Old, L. J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.8.3171 · Cited by 173
A mutant p53 tumor suppressor protein is a target for peptide-induced CD8+ cytotoxic T-cells.
Yanuck, M., Carbone, D., Pendleton, C. D., Tsukui, T., Winter, S. F., Minna, J. D., & Berzofsky, J. A. (1993) · PubMed · Cited by 172
Shirai, M., Arichi, T., Nishioka, M., Nomura, T., Ikeda, K., Kawanishi, K., Engelhard, V. H., Feinstone, S. M., & Berzofsky, J. A. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.154.6.2733 · Cited by 165
Tsomides, T. J., Walker, B. D., & Eisen, H. N. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.24.11276 · Cited by 162
Peptides in positive and negative selection: A delicate balance
Allen, P. M. (1994) · Cell · doi:10.1016/0092-8674(94)90497-9 · Cited by 152
Pardoll, D. M. (1994) · Nature · doi:10.1038/369357a0 · Cited by 150
Irwin, M. J., Heath, W. R., & Sherman, L. A. (1989) · The Journal of Experimental Medicine · doi:10.1084/jem.170.4.1091 · Cited by 136
Self-citationDifferent forms of p53 detected by monoclonal antibodies in non-dividing and dividing lymphocytes
Milner, J. (1984) · Nature · doi:10.1038/310143a0 · Cited by 116
Morrison, J., Elvin, J. G., Latron, F., Gotch, F. M., Moots, R. J., Strominger, J. L., & McMichael, A. J. (1992) · European Journal of Immunology · doi:10.1002/eji.1830220404 · Cited by 112
Alexander, M., Damico, C. A., Wieties, K., Hansen, T. H., & Connolly, J. M. (1991) · The Journal of Experimental Medicine · doi:10.1084/jem.173.4.849 · Cited by 111
Peripheral Tolerance as a Multi‐Step Mechanism
Hämmerling, G. J., Schönrich, G., Ferber, I., & Arnold, B. (1993) · Immunological Reviews · doi:10.1111/j.1600-065x.1993.tb01511.x · Cited by 95
p53, a potential target for tumor-directed T cells
Nijman, H. W., van der Burg, S. H., Vicrboom, M. P. M., Houbiers, J. G. A., Kast, W. M., & Melief, C. J. M. (1994) · Immunology Letters · doi:10.1016/0165-2478(94)90189-9 · Cited by 86
Zeh, H. J., Leder, G. H., Lotze, M. T., Salter, R. D., Tector, M., Stuber, G., Modrow, S., & Storkus, W. J. (1994) · Human Immunology · doi:10.1016/0198-8859(94)90105-8 · Cited by 79
Stuber, G., Leder, G. H., Storkus, W. J., Lotze, M. T., Modrow, S., Székely, L., Wolf, H. J., Klein, E., Kärre, K., & Klein, G. (1994) · European Journal of Immunology · doi:10.1002/eji.1830240341 · Cited by 72
Direct analysis of tumor-associated peptide antigens
Slingluff, C. L., Hunt, D. F., & Engelhard, V. H. (1994) · Current Opinion in Immunology · doi:10.1016/0952-7915(94)90077-9 · Cited by 59
A Transgenic Approach to the Study of Peripheral T‐Cell Tolerance
Miller, J. F. A. P., Morahan, G., Allison, J., & Hoffmann, M. (1991) · Immunological Reviews · doi:10.1111/j.1600-065x.1991.tb00599.x · Cited by 51
Takahashi, K., Sumimoto, H., Suzuki, K., & Ono, T. (1993) · Molecular Carcinogenesis · doi:10.1002/mc.2940080112 · Cited by 39
Fady, C., Gardner, A. M., Gera, J., & Lichtenstein, A. K. (1993) · Cancer Immunology Immunotherapy · doi:10.1007/bf01518456 · Cited by 12
Cited by
Adoptive cell transfer: a clinical path to effective cancer immunotherapy
Rosenberg, S. A., Restifo, N. P., Yang, J. C., Morgan, R. A., & Dudley, M. E. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2355 · Cited by 1,659
Johnson, L. A., Morgan, R. A., Dudley, M. E., Cassard, L., Yang, J. C., Hughes, M. S., Kammula, U. S., Royal, R. E., Sherry, R. M., Wunderlich, J. R., et al. (2009) · Blood · doi:10.1182/blood-2009-03-211714 · Cited by 1,418
Progress in human tumour immunology and immunotherapy
Rosenberg, S. A. (2001) · Nature · doi:10.1038/35077246 · Cited by 1,325
Harris, C. C. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.20.1442 · Cited by 680
Cohen, C. J., Zhao, Y., Zheng, Z., Rosenberg, S. A., & Morgan, R. A. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1450 · Cited by 469
Metadata
- Authors
- Theobald, M., Biggs, J., Dittmer, D., Levine, A. J., & Sherman, L. A.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1995-12-19
- Volume
- 92
- Issue
- 26
- Pages
- 11993-11997
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2080692751
- Cited by
- 304
- References
- 53
- FWCI
- 6.93
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.